These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 23549149)

  • 1. Gatekeepers and enablers: how drug regulators respond to a challenging and changing environment by moving toward a proactive attitude.
    Ehmann F; Papaluca Amati M; Salmonson T; Posch M; Vamvakas S; Hemmings R; Eichler HG; Schneider CK
    Clin Pharmacol Ther; 2013 May; 93(5):425-32. PubMed ID: 23549149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perestroika in pharma: evolution or revolution in drug development?
    FitzGerald GA
    Mt Sinai J Med; 2010; 77(4):327-32. PubMed ID: 20687177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicines regulation and health technology assessment.
    Breckenridge A; Woods K; Walley T
    Clin Pharmacol Ther; 2010 Feb; 87(2):152-4. PubMed ID: 20107448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vulnerable points in the U.S. drug-distribution system.
    Shepherd M
    Manag Care; 2004 Mar; 13(3 Suppl):25-9. PubMed ID: 15074167
    [No Abstract]   [Full Text] [Related]  

  • 5. Towards a European strategy for medicines research (2014-2020): The EUFEPS position paper on Horizon 2020.
    Gaspar R; Aksu B; Cuine A; Danhof M; Takac MJ; Linden HH; Link A; Muchitsch EM; Wilson CG; Ohrngren P; Dencker L
    Eur J Pharm Sci; 2012 Dec; 47(5):979-87. PubMed ID: 23046836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early communication of drug safety concerns: a feasibility study on enhancing interaction between the pharmaceutical industry and regulators.
    Swain E; Morgan S; Brewster W; Kauser S
    Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):232-7. PubMed ID: 20033909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA recognition of first-world drug regulators as means of relieving U.S. drug shortages.
    Hunnisett-Dritz D
    Am J Health Syst Pharm; 2012 Oct; 69(19):1626, 1628. PubMed ID: 22997113
    [No Abstract]   [Full Text] [Related]  

  • 8. Rationale drug therapy: reasons for failure and suggestions for its implementation.
    Mathur GP; Kushwaha KP; Mathur S
    Indian Pediatr; 1993 Jun; 30(6):815-8. PubMed ID: 7726879
    [No Abstract]   [Full Text] [Related]  

  • 9. What can Johnson & Johnson do to remain a giant in the health care industry?
    Carter T
    J Hosp Mark Public Relations; 2002; 14(1):93-103. PubMed ID: 12569997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of factors associated with dose differences between Japan and the United States.
    Arnold FL; Fukunaga S; Kusama M; Matsuki N; Ono S
    Clin Pharmacol Ther; 2014 May; 95(5):542-9. PubMed ID: 24281222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A report from CPhI Worldwide 2013, Fifth Annual Pre-Connect Conference (October 22-24, 2013 - Frankfurt, Germany).
    Kuhrt K; Gilpatrick J
    Drugs Today (Barc); 2013 Nov; 49(11):745-50. PubMed ID: 24308020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. If children ruled the pharmaceutical industry: the need for pediatric formulations.
    Rieder M
    Drug News Perspect; 2010 Sep; 23(7):458-64. PubMed ID: 20862398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ICH: an exclusive club of drug regulatory agencies and drug companies imposing its rules on the rest of the world.
    Prescrire Int; 2010 Aug; 19(108):183-6. PubMed ID: 20939460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The state of innovation in drug development.
    Kola I
    Clin Pharmacol Ther; 2008 Feb; 83(2):227-30. PubMed ID: 18202690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. European Paediatric Formulation Initiative's (EuPFI) 2nd conference commentary--Formulating better medicines for children.
    Salunke S; Hempenstall J; Kendall R; Roger B; Mroz C; Nunn T; Tuleu C
    Int J Pharm; 2011 Oct; 419(1-2):235-9. PubMed ID: 21784141
    [No Abstract]   [Full Text] [Related]  

  • 16. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
    Federsel HJ
    Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ADR: a new global phenomenon, thanks to the ICH.
    Prescrire Int; 2013 Apr; 22(137):88. PubMed ID: 23662314
    [No Abstract]   [Full Text] [Related]  

  • 18. Specifications from a biotechnology industry perspective.
    Garnick RL
    Dev Biol Stand; 1997; 91():31-6. PubMed ID: 9413680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

  • 20. Defining the pharmaceutical system to support proactive drug safety.
    Lewis VR; Hernandez A; Meadors M
    Curr Drug Saf; 2013 Feb; 8(1):25-39. PubMed ID: 23656445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.